{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:51Z","timestamp":1740126831751,"version":"3.37.3"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"S 01","funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["K23 HL136851"],"award-info":[{"award-number":["K23 HL136851"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"crossref","award":["T15LM007092"],"award-info":[{"award-number":["T15LM007092"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>\n            Objectives\u2003Our objective was to compare rates of hospitalizations for respiratory illnesses in preterm and full-term (FT) children for 4 years before and after the 2014 update to the American Academy of Pediatrics (AAP) respiratory syncytial virus (RSV) immunoprophylaxis guidance, which restricted eligibility among infants born at 29 to 34 weeks in the first winter and all preterm infants in the second winter after neonatal discharge.<\/jats:p><jats:p>\n            Study Design\u2003We conducted pre-post and interrupted time series analyses on claims data from a commercial national managed care plan. We compared the number of RSV and all respiratory hospital admissions in the first and second RSV seasons after neonatal discharge among a cohort of preterm children, regardless of palivizumab status, in the 4 years before and after the implementation of the 2014 palivizumab eligibility change. A FT group was included for reference.<\/jats:p><jats:p>\n            Results\u2003The cohort included 821 early preterm (EP, &lt;29 weeks), 4,790 moderate preterm (MP, 29\u201334 weeks), and 130,782 FT children. Palivizumab use after the policy update decreased among MP children in the first and second RSV seasons after neonatal discharge, without any change in the odds of hospitalization with RSV or respiratory illness. For the EP group, there was no change in the rate of palivizumab or the odds of hospitalization with RSV or respiratory illness after the policy update. For the FT group, there was a slight decrease in odds of hospitalization post-2014 after the policy update. The interrupted time series did not reveal any secular trends over time in hospitalization rates among preterm children. Following the policy change, there were cost savings for MP children in the first and second RSV seasons, when accounting for the cost of hospitalizations and the cost of palivizumab.<\/jats:p><jats:p>\n            Conclusion\u2003Hospitalizations for RSV or respiratory illness did not increase, and cost savings were obtained after the implementation of the 2014 AAP palivizumab prophylaxis policy.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/a-1845-2184","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T23:13:22Z","timestamp":1651878802000},"page":"e133-e141","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update"],"prefix":"10.1055","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8422-791X","authenticated-orcid":false,"given":"Jonathan C.","family":"Levin","sequence":"additional","affiliation":[{"name":"Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts"},{"name":"Division of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Beam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathe P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lystra P.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts"},{"name":"Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"C B Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006","volume":"31","author":"L J Stockman","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1097\/INF.0000000000002279","article-title":"Respiratory virus epidemiology among US infants with severe bronchiolitis: analysis of 2 multicenter, multiyear cohort studies","volume":"38","author":"K Hasegawa","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"S Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"02","key":"ref5","first-page":"199","article-title":"Respiratory syncytial virus infection in children with bronchopulmonary dysplasia","volume":"82","author":"J R Groothuis","year":"1988","journal-title":"Pediatrics"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid","volume":"137","author":"T G Boyce","year":"2000","journal-title":"J Pediatr"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1542\/peds.2014-2151","article-title":"Respiratory syncytial virus-associated mortality in hospitalized infants and young children","volume":"135","author":"C L Byington","year":"2015","journal-title":"Pediatrics"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201603-0658OC","article-title":"Mortality due to respiratory syncytial virus. burden and risk factors","volume":"195","author":"S Geoghegan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis","volume":"52","author":"R T Stein","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","article-title":"Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV","volume":"102","author":"American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn","year":"1998","journal-title":"Pediatrics"},{"issue":"04","key":"ref12","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","author":"T Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"e20184064","DOI":"10.1542\/peds.2018-4064","article-title":"Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review","volume":"143","author":"S Mac","year":"2019","journal-title":"Pediatrics"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s41669-017-0042-3","article-title":"Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants","volume":"2","author":"A Shahabi","year":"2018","journal-title":"Pharmacoecon Open"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"From the American Academy of Pediatrics: policy statements\u2014modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections","volume":"124","author":"Committee on Infectious Diseases.","year":"2009","journal-title":"Pediatrics"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee","year":"2014","journal-title":"Pediatrics"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapediatrics.2013.2636","article-title":"Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study","volume":"167","author":"A G Winterstein","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/ANC.0000000000000367","article-title":"Evaluation of the financial and health burden of infants at risk for respiratory syncytial virus","volume":"17","author":"S M Blake","year":"2017","journal-title":"Adv Neonatal Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2016.10.074","article-title":"Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience","volume":"181","author":"B Rajah","year":"2017","journal-title":"J Pediatr"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0036-1584147","article-title":"SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis","volume":"34","author":"E J Anderson","year":"2017","journal-title":"Am J Perinatol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0037-1606352","article-title":"The 2014-2015 national impact of the 2014 American Academy of Pediatrics Guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States","volume":"35","author":"A M Kong","year":"2018","journal-title":"Am J Perinatol"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0038-1660466","article-title":"Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012-2016","volume":"35","author":"M Goldstein","year":"2018","journal-title":"Am J Perinatol"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0039-1681014","article-title":"SENTINEL1: two-season study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis","volume":"37","author":"E J Anderson","year":"2020","journal-title":"Am J Perinatol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1542\/peds.2012-3877","article-title":"Trends in bronchiolitis hospitalizations in the United States, 2000-2009","volume":"132","author":"K Hasegawa","year":"2013","journal-title":"Pediatrics"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"e0205399","DOI":"10.1371\/journal.pone.0205399","article-title":"Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations","volume":"13","author":"M V Bennett","year":"2018","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1055\/s-0040-1709127","article-title":"Unintended consequences following the 2014 American Academy of Pediatrics policy change for palivizumab prophylaxis among infants born at less than 29 weeks' gestation","volume":"38","author":"M Goldstein","year":"2021","journal-title":"Am J Perinatol"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41372-020-0635-z","article-title":"Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016","volume":"40","author":"A L Beam","year":"2020","journal-title":"J Perinatol"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41372-021-00930-0","article-title":"Medication utilization in children born preterm in the first two years of life","volume":"41","author":"J C Levin","year":"2021","journal-title":"J Perinatol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.15585\/mmwr.mm6702a4","article-title":"Respiratory syncytial virus seasonality\u2014United States, 2014-2017","volume":"67","author":"E B Rose","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamapediatrics.2014.3804","article-title":"Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection","volume":"169","author":"A Gutfraind","year":"2015","journal-title":"JAMA Pediatr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1542\/peds.106.S3.937","article-title":"Effect of a reduced postpartum length of stay program on primary care services use by mothers and infants","volume":"106","author":"K D Mandl","year":"2000","journal-title":"Pediatrics"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0009922814546040","article-title":"The underrecognized burden of respiratory syncytial virus among infants presenting to US emergency departments","volume":"54","author":"D Makari","year":"2015","journal-title":"Clin Pediatr (Phila)"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1845-2184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:07:33Z","timestamp":1730812053000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1845-2184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":32,"journal-issue":{"issue":"S 01","published-online":{"date-parts":[[2024,5,13]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1845-2184","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"type":"print","value":"0735-1631"},{"type":"electronic","value":"1098-8785"}],"subject":[],"published-other":{"date-parts":[[2022,5,6]]},"published":{"date-parts":[[2022,5,6]]}}}